RNA vaccine shows promise in fight against malaria

NCT ID NCT06069544

Completed ⭐️ VACCINE ⭐️ Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Apr 18, 2026 · Last updated Jun 18, 2026 · Updated 9 times

Summary

This study tested an experimental RNA-based vaccine (BNT165e) to prevent malaria in 163 healthy adults who had never had the disease. The vaccine uses three RNA pieces to train the immune system against the malaria parasite. The main goals were to check safety and see how well the vaccine triggers an immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AMR Knoxville

Knoxville, Tennessee, 37909, United States
AMR Las Vegas

Las Vegas, Nevada, 89119, United States
AMR Tempe

Tempe, Arizona, 85281, United States
Clinical Trials of Texas

San Antonio, Texas, 78229, United States
University of Maryland, Center for Vaccine Development

Baltimore, Maryland, 21201, United States

Conditions

The condition(s) this trial relates to.

malaria Plasmodium falciparum malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA MALARIA